Ticagrelor Tablet
Product Images NDC 50228-522

Product Visual Gallery

This gallery contains 25 technical images submitted to the FDA as part of the official labeling for Ticagrelor (NDC 50228-522). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sciegen Pharmaceuticals Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Ticagrelor Tablets 1)

A Kaplan-Meier curve comparing cumulative event percentages over 360 days between ticagrelor 90 mg and clopidogrel, showing a higher cumulative event rate for ticagrelor. The graph includes a table with patient counts and event percentages, as well as a risk table indicating the number of patients at risk at various time points for each drug.*

FDA Label Image

9 (Ticagrelor Tablets 10)

A pharmacokinetic chart illustrating the mean effect and 90% confidence interval of various interacting drugs on ticagrelor concentration. The chart compares changes in Cmax and AUC relative to each interacting drug alone, with recommendations for dose adjustments, showing maximum simvastatin dose limits and no dose adjustment advice for other drugs listed.*

FDA Label Image

10 (Ticagrelor Tablets 11)

A Kaplan-Meier cumulative incidence curve comparing ticagrelor 90 mg with clopidogrel over 360 days from randomization. The graph shows cumulative percentage on the y-axis versus days on the x-axis, with ticagrelor represented by a solid line and clopidogrel by a dashed line. Patient event numbers and statistics are detailed in a legend box within the graph.*

FDA Label Image

11 (Ticagrelor Tablets 12)

A forest plot comparing the hazard ratios (HR) and 95% confidence intervals for ticagrelor versus clopidogrel across various patient characteristics, treatment approaches, and demographics. The plot displays subgroups including geographic region, aspirin use, treatment methods, prior medical history, age groups, sex, and race, indicating relative effectiveness between ticagrelor and clopidogrel.*

FDA Label Image

12 (Ticagrelor Tablets 13)

A data table comparing ticagrelor versus clopidogrel use across US and Non-US regions, segmented by ASA dose in mg. The table includes patient counts (N), event counts (E), hazard ratios (HR) with 95% confidence intervals (CI), and a forest plot showing treatment effect estimates. The plot visually compares ticagrelor and clopidogrel outcomes across different ASA dose groups and regions.*

FDA Label Image

13 (Ticagrelor Tablets 14)

A Kaplan-Meier cumulative incidence curve comparing ticagrelor 90 mg, ticagrelor 60 mg, and placebo over approximately 1320 days from randomization. The graph shows cumulative event percentages with ticagrelor 90 mg and 60 mg groups having lower event rates compared to placebo. Patient numbers at risk are listed below the x-axis by time points. A statistical summary table with hazard ratios and p-values is included.*

FDA Label Image

14 (Ticagrelor Tablets 15)

A forest plot chart comparing the hazard ratios (HR) with 95% confidence intervals for multiple patient subgroups between ticagrelor and placebo treatments. It presents subgroup categories like age, sex, race, weight, BMI, geographic region, time from qualifying MI, type of MI, diabetes status, history of PCI, stent type, and prior receptor blocker treatment, showing the relative effect of ticagrelor versus placebo in each category.*

FDA Label Image

15 (Ticagrelor Tablets 16)

A line graph showing the cumulative percentage of events over months from randomization comparing ticagrelor (solid line) and placebo (dashed line). The vertical axis represents cumulative percentage, and the horizontal axis shows time in months up to 54. The graph includes the number of patients at risk for each group at various time points.*

FDA Label Image

16 (Ticagrelor Tablets 17)

A forest plot comparing hazard ratios (HR) and 95% confidence intervals (CI) for ticagrelor versus placebo across multiple patient subgroups categorized by age, sex, race, body mass index, geographic region, aspirin dose, HbA1c, eGFR, insulin use, history of angina, diabetes status, multivessel coronary artery disease, PCI history, time since procedures (PCI or CABG), current smoking status, and duration of diabetes. Squares represent point estimates with horizontal lines indicating confidence intervals, distributed around a vertical line marking HR=1 (no effect).*

FDA Label Image

17 (Ticagrelor Tablets 18)

A Kaplan-Meier cumulative incidence curve comparing ticagrelor 90 mg twice daily and placebo over 34 days from randomization. The y-axis shows cumulative percentage events, with ticagrelor showing lower event rates compared to placebo. Numbers at risk for both groups are presented below the x-axis at various time points.*

FDA Label Image

18 (Ticagrelor Tablets 19)

A forest plot graph depicting hazard ratios (HR) with 95% confidence intervals for various patient characteristics comparing ticagrelor and placebo outcomes. The graph presents subgroup analysis by age, sex, race, weight, BMI, geographic region, diagnosis, stroke severity, time intervals, diabetes, hypertension, prior ischemic events, statin treatment, and smoking status. Ticagrelor's comparative efficacy versus placebo is illustrated along a horizontal axis labeled from 0.5 to 2.0, with points and confidence bars for each subgroup.*

FDA Label Image

2 (Ticagrelor Tablets 2)

A bar graph comparing the percentage of patients who had an event following CABG over a number of days. The x-axis is labeled with days (1, 2, 3, 4, 5, 6, 7, >=8), and the y-axis represents the percentage. Two data series are shown, labeled T and C, with solid and striped bars respectively. A table below the graph provides patient counts for T and C for each time point.*

FDA Label Image

3 (Ticagrelor Tablets 3)

A line graph showing the cumulative percentage of events over time in months from randomization for two groups: ticagrelor and placebo. The x-axis represents time in months up to 54, and the y-axis represents the cumulative event percentage from 0 to 7%. A solid line represents the ticagrelor group with higher cumulative percentages, and a dashed line represents the placebo group with lower percentages. A table below shows the number at risk for each group at various time points.*

FDA Label Image

4 (Ticagrelor Tablets 4)

A Kaplan-Meier curve chart comparing cumulative event percentages over days from randomization between ticagrelor 90 mg twice daily and placebo groups. The chart includes event counts and KM percentages for both groups, with a time axis spanning approximately 0 to 34 days. The ticagrelor group shows higher cumulative events than placebo throughout.*

FDA Label Image

Abc (Ticagrelor Tablets 5)

Chemical structure diagram of ticagrelor, showing its molecular framework with various functional groups and ring systems, including fluorinated aromatic and sugar moieties.*

FDA Label Image

5 (Ticagrelor Tablets 6)

A line graph comparing the percent inhibition of platelet aggregation (IPA) induced by 20 µM ADP over 8 hours for Ticagrelor 180 mg, Clopidogrel 600 mg, and placebo. Ticagrelor shows the highest IPA reaching near 90%, Clopidogrel shows moderate IPA around 50%, and placebo shows minimal IPA below 10%. Time in hours is on the x-axis.*

FDA Label Image

Ticagrelor-tablets-60mg-1000s (Ticagrelor Tablets 60mg 1000s)

Label for ticagrelor tablets 60 mg by ScieGen Pharmaceuticals Inc. The label shows the drug name, dosage strength (60 mg), package size (1,000 tablets), and Rx only status. It includes storage instructions and a warning to keep out of reach of children. The ScieGen logo is visible at the bottom.*

FDA Label Image

Ticagrelor-tablets-60mg-30s (Ticagrelor Tablets 60mg 30s)

Label for Ticagrelor Tablets 60 mg oral tablets, manufactured by ScieGen Pharmaceuticals Inc. The label includes dosage instructions, storage conditions at 25°C with allowable excursions, a warning to keep out of reach of children, and states a package count of 30 tablets. The NDC number 50228-521-30 and a barcode are also displayed.*

FDA Label Image

Ticagrelor-tablets-60mg-60s (Ticagrelor Tablets 60mg 60s)

Label for Ticagrelor Tablets 60 mg oral tablets, containing 60 tablets per bottle. The label includes dosage and storage instructions, a barcode, and the manufacturer ScieGen Pharmaceuticals Inc. It also states 'Rx Only' and advises dispensing the accompanying Medication Guide to patients.*

FDA Label Image

6 (Ticagrelor Tablets 7)

A line graph comparing IPA (%) induced by 20 µM ADP over time for ticagrelor, clopidogrel, and placebo. The x-axis shows time in days, and the y-axis shows IPA (%) values. Ticagrelor is represented by circles, clopidogrel by triangles, and placebo by squares. A smaller inset graph shows IPA (%) over time in hours for the same groups.*

FDA Label Image

7 (Ticagrelor Tablets 8)

A forest plot chart illustrating the mean effect and 90% confidence intervals for ticagrelor and comparator AR-C124910XX across intrinsic factors like age, gender, ethnicity, renal and hepatic impairment. It shows change relative to reference for pharmacokinetics parameters (Cmax and AUC) with a recommendation column indicating no dose adjustment for various subgroups.*

FDA Label Image

8 (Ticagrelor Tablets 9)

A scatter plot chart titled 'Mean Effect and 90% CI' depicting the interaction effects of various drugs on Ticagrelor and AR-C124910XX. The x-axis shows 'Change relative to reference' with values ranging from 0 to over 8, and the y-axis lists interacting drugs such as Ketoconazole, Diltiazem, Rifampin, Aspirin, Heparin, Morphine, and others. Two pharmacokinetic parameters, Cmax (square) and AUC (triangle), are plotted for each drug interaction alongside recommendations for dose adjustments or concomitant use.*

FDA Label Image

Ticagrelor-tablets-90mg-1000s (Ticagrelor Tablets 90mg 1000s)

Label for Ticagrelor Tablets 90 mg by ScieGen Pharmaceuticals Inc. The label includes dosage information, warnings, storage instructions, and states a package size of 1,000 tablets. It features a barcode and the phrase NO VARNISH in orange text.*

FDA Label Image

Ticagrelor-tablets-90mg-30s (Ticagrelor Tablets 90mg 30s)

Ticagrelor 90 mg tablets packaging label from ScieGen Pharmaceuticals Inc. The label indicates the strength as 90 mg per tablet, with a package containing 30 tablets. The label includes storage instructions and a warning to keep out of reach of children, plus a barcode and NDC 50228-522-30.*

FDA Label Image

Ticagrelor-tablets-90mg-60s (Ticagrelor Tablets 90mg 60s)

Label for Ticagrelor Tablets 90 mg oral tablets by ScieGen Pharmaceuticals Inc. The label indicates 60 tablets per unit, NDC 50228-522-60, and instructs to dispense the accompanying Medication Guide. Storage temperature and safety warnings are also included on the label.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.